Pediatrix Medical Group, Inc. MD

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

MD hizo una división de acciones (split) de 2:1 el 20 de diciembre de 2013: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 22 sept

  Can Pediatrix Sustain Growth Despite Lower Patient Volumes?

  Pediatrix Medical Group (MD) reported 4% YoY revenue growth to $487.8 million in Q2 2026, driven by improved reimbursement and higher patient acuity, offsetting a 2.1% decline in patient volumes. The company reaffirmed its 2026 adjusted EBITDA guidance of $280-$300 million, though volume trends and easing collection benefits remain key risks.

  

• Zacks Investment Research 4 sept

  Cencora (COR) Up 3.8% Since Last Earnings Report: Can It Continue?

  Cencora reported Q3 fiscal 2026 adjusted EPS of $4.48, beating consensus estimates by 2.5%, with 12% year-over-year earnings growth. Revenue rose 5.1% to $84.76 billion but slightly missed expectations. The company raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95 and increased operating income growth outlook to 13-14%. However, post-earnings estimates have trended downward, and the stock received a Zacks Rank #3 (Hold) rating.

  

• Zacks Investment Research 3 sept

  Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?

  Pediatrix Medical Group beat Q2 2026 earnings expectations with adjusted EPS of 63 cents (10.5% above consensus) and revenue of $487.8 million (2.2% above estimate), driven by improved cash collection and favorable payor mix. However, the company faced headwinds from lower patient volumes and higher operating costs. Management reaffirmed 2026 adjusted EBITDA guidance of $280-$300 million. The stock has gained 3.4% since the earnings report and carries a Zacks Rank #3 (Hold) rating with an overall VGM Score of A.